{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:51:00Z","timestamp":1761630660279,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.annder.2013.07.012","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T14:00:45Z","timestamp":1376402445000},"page":"797-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Maladie de Sneddon-Wilkinson \u00e9chappant \u00e0 l\u2019infliximab et \u00e0 l\u2019\u00e9tanercept\u00a0: efficacit\u00e9 de l\u2019adalimumab"],"prefix":"10.1016","volume":"140","author":[{"given":"M.","family":"Versini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mantoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Passeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2013.07.012_bib0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2230.2008.02706.x","article-title":"Subcorneal pustular dermatosis: 50\u00a0years on","volume":"33","author":"Cheng","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2013.07.012_bib0010","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/archderm.137.12.1571","article-title":"Infliximab (anti-tumor necrosis factor-alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease)","volume":"137","author":"Voigtl\u00e4nder","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.07.012_bib0015","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/0190-9622(91)70290-I","article-title":"Role of tumor necrosis factor-alpha in Sneddon-Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo","volume":"25","author":"Grob","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.07.012_bib0020","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2230.2005.01902.x","article-title":"Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids","volume":"30","author":"Bonifati","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2013.07.012_bib0025","first-page":"AB46","article-title":"Sneddon-Wilkinson's syndrome: a therapeutic challenge","volume":"56","author":"Raimondo","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.07.012_bib0030","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1002\/art.21402","article-title":"Sneddon-Wilkinson disease in a patient with rheumatoid arthritis","volume":"52","author":"Iobst","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annder.2013.07.012_bib0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1540-9740.2007.888109.x","article-title":"Successful treatment of long-standing, recalcitrant subcorneal pustular dermatosis with etanercept","volume":"6","author":"Bedi","year":"2007","journal-title":"SKINmed"},{"key":"10.1016\/j.annder.2013.07.012_bib0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2230.2008.02905.x","article-title":"Sneddon-Wilkinson disease treated with etanercept: report of two cases","volume":"34","author":"Berk","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2013.07.012_bib0045","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0961203309103053","article-title":"The case of SLE associated Sneddon-Wilkinson pustular disease successfully and safely treated with infliximab","volume":"18","author":"Naretto","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.annder.2013.07.012_bib0050","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1684\/ejd.2010.0957","article-title":"Subcorneal pustular dermatosis treated successfully with adalimumab","volume":"20","author":"De Encarna\u00e7\u00e3o Roque Diamantino","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2013.07.012_bib0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrugs antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2013.07.012_bib0060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813008545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813008545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:01:08Z","timestamp":1758970868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963813008545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0151963813008545"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2013.07.012","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie de Sneddon-Wilkinson \u00e9chappant \u00e0 l\u2019infliximab et \u00e0 l\u2019\u00e9tanercept\u00a0: efficacit\u00e9 de l\u2019adalimumab","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2013.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}